AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01957072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention
Description: The behaviour change intervention consists of~1. feedback via a web-based food diary~2. 'coaching' with problem-solving and implementation plans~The intensive intervention phase consists of 2 home visits, 8 telephone calls and 6 reminder emails.~The maintenance phase consists of 3 telephone calls and 4 reminder emails.
Study NCT01957072 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behaviour change intervention
Description: The behaviour change intervention consists of~1. feedback via a web-based food diary~2. 'coaching' with problem-solving and implementation plans~The intensive intervention phase consists of 2 home visits, 8 telephone calls and 6 reminder emails.~The maintenance phase consists of 3 telephone calls and 4 reminder emails.
Study NCT01254266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inpatient hospitalization and follow up
Description: An inpatient program and a 1-year weekly follow up that include multi-disciplinary interventions for weight reduction and maintenance.
Study NCT01254266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inpatient treatment and follow up
Description: one month inpatient treatment followed by a year-long follow up on the inpatient unit.
Study NCT01254266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: bariatric surgery.
Study NCT01864317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scanning Laser Polarimetry
Description: Measurement of retinal nerve fiber thickness
Study NCT01864317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Humphrey Perimetry
Description: Visual Field Testing
Study NCT01864317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Humphrey Perimetry
Description: Visual Field Testing
Study NCT01864317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Applanation Tonometry
Description: Measurement of Intraocular Pressure
Study NCT01864317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Applanation Tonometry
Description: Measurement of Intraocular Pressure
Study NCT02858102 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity program
Description: The intensity of physical activity will be adapted to the possibilities of the participants making individualized proposals to encourage participants to acquire active lifestyle habits to improve their health. All sessions end with a routine of relaxation and passive stretching. Simultaneously self-employment is controlled outside the guided sessions.
Study NCT01587274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500mg twice/ day x 10 days
Study NCT01587274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine
Description: Cyclobenzaprine 5-10mg three times/ day x 10 days
Study NCT01587274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/ acetaminophen
Description: Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days
Study NCT01192204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% FBR containing bioadhesive gel
Description: 0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
Study NCT01192204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: 0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
Study NCT04257604 — intervention group
Intervention type: DRUG
Intervention: Perampanel
Description: Perampanel tablets.
Study NCT01254266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inpatient treatment with follow up
Description: 1 month inpatient treatment followed by a year-long follow up on the inpatient unit.
Study NCT01157806 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course of palliative radiotherapy
Description: 5x5 Gy + XELOX 7 days after radiotherapy
Study NCT00755404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD Solution
Description: Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 180 days.
Study NCT00755404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD solution containing L-carnitine
Description: Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 180 days.
Study NCT03198975 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance image
Description: Histologically-diagnosed primary HCC after curative hepatectomy. The magnetic resonance image will be imported into the software ,and the radiomic textural features will be automatically extracted by the Analysis-Kit software.The high-throughput extracted features will be then selected and a prediction model will be developed in the training set in which patients were collected from a retrospective study. In this project, an independent validation set will be collected and used to validate the prediction accuracy of the model.
Study NCT00499174 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: Radical prostatectomy
Study NCT00499174 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: brachytherapy
Description: high dose rate temporary seed implant; permanent seed implant.
Study NCT00499174 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: external beam radiation therapy
Description: 3D conformal radiation therapy; intensity modulated radiation therapy.
Study NCT00499174 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsies
Description: Periodic repeat biopsies
Study NCT04432103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients
Description: Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 severe cases.
Study NCT04432103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients
Description: Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 critical cases.
Study NCT04126213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV MAT 60 µg
Description: One single dose of RSV MAT 60 µg vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
Study NCT04126213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV MAT 120 µg
Description: One single dose of RSV MAT 120 µg vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
Study NCT04126213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single dose of placebo (NaCl solution) administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
Study NCT01371266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Honey
Description: 60.7 grams orally daily times 14 days
Study NCT01371266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Fructose Corn Syrup 55 (HFCS 55)
Description: 65.7 gram daily orally times 14 days
Study NCT01371266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CHO (sugar)
Description: 50 grams daily orally times 14 days
Study NCT02987959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-228
Description: TAK-228 is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128) targets 2 distinct mTOR complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
Study NCT01183221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Syntocinon
Description: One dose of 24 IU (3 sprays/nostril)
Study NCT01183221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon
Description: One dose of 24 IU (3 sprays/nostril)
Study NCT01183221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal Placebo
Study NCT01183221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intranasal Placebo
Study NCT02674321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-809
Study NCT02890030 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: * Neurotoxicity~* Medications of interest~* General health~* Family history
Study NCT01294826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: Weekly intravenous infusion on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of AUY922 is 40, 55, and 70 mg/m2 will be used.
Study NCT01294826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered after each AUY922 infusion, intravenously on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression.
Study NCT03582826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counselling
Description: Behavioral nutritional counselling delivered via the Internet.
Study NCT03582826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress-reduction counseling
Description: The psycho-behavioral intervention includes administering questionnaires and monthly maintenance psychological support delivered via the Internet.
Study NCT04178070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB224 2mg
Description: 2mg (100μL), single dose, abdominal subcutaneous injection
Study NCT04178070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB224 5mg
Description: 5mg (250μL), single dose, abdominal subcutaneous injection
Study NCT04178070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB224 10mg
Description: 10mg (500μL), single dose, abdominal subcutaneous injection
Study NCT04178070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB224 15mg
Description: 15mg (750μL), single dose, abdominal subcutaneous injection
Study NCT04178070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB224 20mg
Description: 20mg (1mL), single dose, abdominal subcutaneous injection
Study NCT04178070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB224 30mg
Description: 30mg (1.5mL), single dose, abdominal subcutaneous injection
Study NCT04178070 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 2mg
Description: 2mg (100μL), single dose, abdominal subcutaneous injection
Study NCT04178070 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 5mg
Description: 5mg (250μL), single dose, abdominal subcutaneous injection
Study NCT03616847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Hallux valgus/hallux rigidus surgery with the calf tourniquet remaining in situ until the wound is closed.
Study NCT03616847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tourniquet release
Description: Hallux valgus/hallux rigidus surgery with the calf tourniquet released five minutes before the wound is closed.
Study NCT02158455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NT SVG grafts
Study NCT03390296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study NCT02158455 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NT SVG grafts
Study NCT04312048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Description: one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion
Study NCT01270724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).
Description: Two to four cycles of induction therapy with GemPOx followed by consolidation and ASCT.
Study NCT02805959 — intervention group
Intervention type: DEVICE
Intervention: MTS2
Study NCT04312048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet of placebo vaginally 3 hours prior to copper IUD insertion
Study NCT01864655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: oral drug given to experimental group
Study NCT03390296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT01864655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given to placebo group
Study NCT01831648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Study NCT03390296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV
Study NCT03390296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib
Description: Given PO
Study NCT03390296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib Maleate
Description: Given PO
Study NCT03390296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT01119066 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total body irradiation
Description: dose of 1375-1500 cGy
Study NCT01119066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 5 mg/kg/day x 2 or 10 mg/kg/day x 1
Study NCT01119066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).
Study NCT01119066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
Study NCT01119066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70mg/m2/day x 2
Study NCT01534494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: two doses of 0.3 mg/kg PO and 0.4 mg/kg PO, separated by 4 weeks in combination with 12 weeks of manualized outpatient psychosocial treatment including preparation, debriefing, and motivational enhancement therapy.
Study NCT04135040 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Amino Acid
Description: 8 different lysine intakes (L-Amino Acid and food) will be tested for 8 hours each.
Study NCT02680457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Insulin Degludec 10 IU SC every 24 hours for 6 days
Study NCT02680457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Insulin Glargine 10 IU SC every 24 hours for 6 days
Study NCT02724592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: self assembling peptide P11-4 (Curodont™ Repair)
Description: Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions
Study NCT02724592 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fluoride varnish (Duraphat®)
Description: Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions
Study NCT02724592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fluoride varnish (Duraphat®)
Description: Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions
Study NCT00140790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: valsartan 40 or 160 (80) mg per day
Study NCT03764787 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiation+PD-1 Ab
Description: combination of proton radiotherapy with PD-1 antibody
Study NCT03459677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back2School
Description: Modular Trans-diagnostic Cognitive Behavioral Therapy treating school absenteeism in youths
Study NCT03459677 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Aarhus municipality's treatment as usual for youths presenting school absenteeism
Study NCT02317874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02317874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02317874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study NCT00921154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Description: Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods with a 14 day wash-out period. Doses will be administered after an overnight fast.
Study NCT02213744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-302
Study NCT02213744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study NCT02213744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study NCT02213744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Study NCT01963780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCS Lung Preservation
Study NCT01153308 — intervention group
Intervention type: OTHER
Intervention: Observational Study
Description: This is an Observational study
Study NCT01119066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25mg/m2/ day x 5
Study NCT01119066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 20mg/m2/ day x 5 (or, for children \<18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval)
Study NCT01119066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (CliniMACS) T-cell depleted PBSC Transplant
Study NCT00407836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cell vaccination
Description: Approximately 10-20 million glutaraldehyde fixed CD4 responsive autologous T cells in 1-2 ml, per vaccine injection.
Study NCT00407836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cell vaccination
Description: Approximately 10-20 million autologous CD4 reactive T cells per each vaccine injection
Study NCT00821158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antioxidant
Description: Antioxidant iv bolus
Study NCT00821158 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet and iv
Study NCT00821158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory drug
Description: Anti-inflammatory tablet
Study NCT03940989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HABIT-ILE
Description: Goal-directed, task-specific training for both the upper (UE) and lower extremity (LE) and postural control.
Study NCT00839280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpanthenol foam spray, new formulation
Description: 2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
Study NCT00839280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexpanthenol foam spray, old formulation
Description: 2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
Study NCT03794440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg IV d1， Q3W
Study NCT03794440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI305
Description: 15mg/kg IV d1， Q3W
Study NCT03794440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400mg PO BID
Study NCT04277546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab Maintenance Dose
Description: Completers in the lead-in study D5272C00001 (Legacy #3151-201-008) will receive a maintenance dose of brazikumab administered subcutaneously every 4 weeks up to Week 52 (Group A). The SC dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered.
Study NCT04277546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab Induction Dose
Description: Participants in the lead-in study D5272C00001 (Legacy #3151-201-008) who have not responded to treatment and have met criteria for rescue treatment are considered inadequate/non-responders (Group B). In these eligible participants, IV induction dosing of brazikumab at Week 0, Week 4, and Week 8 will be administered, followed by brazikumab administered subcutaneously every 4 weeks thereafter (up to Week 52).